• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Astria Therapeutics Inc.

    8/12/24 4:56:37 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXS alert in real time by email
    S-8 1 tm2421258d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 12, 2024

     

    Registration No. 333-   

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Astria Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

      Delaware   26-3687168  
      (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification No.)
     

     

     

    22 Boston Wharf Road, 10th Floor

    Boston, Massachusetts

     

     

     

    02210

     
      (Address of Principal Executive Offices)   (Zip Code)  

     

    Second Amended and Restated 2015 Stock Incentive Plan

    2015 Employee Stock Purchase Plan

    2022 Inducement Stock Incentive Plan, as amended

    (Full Title of the Plan)

     

    Benjamin Harshbarger

    Chief Legal Officer
    22 Boston Wharf Road, 10th Floor
    Boston, Massachusetts 02210

    (Name and Address of Agent For Service)

     

    (617) 349-1971

    (Telephone Number, Including Area Code, of Agent For Service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8, relating to the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective.

     

    Accordingly, this Registration Statement incorporates by reference the contents of:

     

    · the Registration Statement on Form S-8, File No. 333-206394, filed with the Securities and Exchange Commission (the “Commission”) on August 14, 2015, by the Registrant, relating to the Registrant’s Amended and Restated 2008 Equity Incentive Plan, as amended, 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-210229, filed with the Commission on March 16, 2016, by the Registrant, relating to the Registrant’s 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-216793, filed with the Commission on March 17, 2017, by the Registrant, relating to the Registrant’s 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-223721, filed with the Commission on March 16, 2018, by the Registrant, relating to the Registrant’s 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-229643, filed with the Commission on February 13, 2019, by the Registrant, relating to the Registrant’s Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-239114, filed with the Commission on June 12, 2020, by the Registrant, relating to the Registrant’s Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-258633, filed with the Commission on August 9, 2021, by the Registrant, relating to the Registrant’s Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

     

    · the Registration Statement on Form S-8, File No. 333-263459, filed with the Commission on March 10, 2022, by the Registrant, relating to the Registrant’s Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan; and

     

    · the Registration Statement on Form S-8, File No. 333-273773, filed with the Commission on August 7, 2023, by the Registrant, relating to the Registrant’s Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

      Item 8. Exhibits.

     

    The following exhibits are incorporated herein by reference:

     

    EXHIBIT INDEX

     

            Incorporated by Reference      
     Exhibit
    Number
      Description of Exhibit   Form   File
    Number
      Date of Filing   Exhibit
    Number
      Filed
    Herewith
     
    4.1   Restated Certificate of Incorporation of the Registrant, as amended   8-K   001-37467   June 6, 2023   3.2      
                               
    4.2   Amended and Restated By-Laws of the Registrant   8-K   001-37467   June 6, 2023   3.1      
                               
    5.1   Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant                   X  
                               
    23.1   Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)                   X  
                               
    23.2   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm                   X  
                               
    24.1   Power of attorney (included on the signature pages of this registration statement)                   X  
                               
    99.1   Second Amended and Restated 2015 Stock Incentive Plan   10-Q   001-37467   August 12, 2024   10.1      
                               
    99.2   2015 Employee Stock Purchase Plan   10-Q   001-37467   May 12, 2022   10.7      
                               
    99.3   2022 Inducement Stock Incentive Plan, as amended   8-K   001-37467   December 20, 2023   99.1      
                               
    107   Filing Fee Table                   X  

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts, on this 12th day of August, 2024.

     

      ASTRIA THERAPEUTICS, INC.
         
      By: /s/ Jill C. Milne
        Jill C. Milne
        President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Astria Therapeutics, Inc., hereby severally constitute and appoint Jill C. Milne, Benjamin Harshbarger and Noah C. Clauser, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Astria Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jill C. Milne  

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

      August 12, 2024
    Jill C. Milne      
             
    /s/ Noah Clauser   Chief Financial Officer   August 12, 2024
    Noah Clauser   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Kenneth Bate   Chairman of the Board of Directors   August 12, 2024
    Kenneth Bate        
             
    /s/ Sunil Agarwal   Director   August 12, 2024
    Sunil Agarwal        
             
    /s/ Joanne Beck   Director   August 12, 2024
    Joanne Beck        
             
    /s/ Frederick P. Callori   Director   August 12, 2024
    Frederick P. Callori        
             
    /s/ Hugh Cole   Director   August 12, 2024
    Hugh Cole        
             
    /s/ Michael Kishbauch   Director   August 12, 2024
    Michael Kishbauch        
             
    /s/ Gregg Lapointe   Director   August 12, 2024
    Gregg Lapointe        
             
    /s/ Jonathan Violin   Director   August 12, 2024
    Jonathan Violin        

     

     

    Get the next $ATXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXS

    DatePrice TargetRatingAnalyst
    11/12/2025Overweight → Neutral
    Cantor Fitzgerald
    9/17/2025$16.00 → $20.00Buy
    H.C. Wainwright
    4/29/2025$47.00Overweight
    Cantor Fitzgerald
    1/31/2025$26.00Mkt Outperform
    JMP Securities
    7/29/2024$35.00Buy
    TD Cowen
    3/28/2023$18.00Outperform
    Evercore ISI
    9/29/2021$20.00Buy
    Jefferies
    More analyst ratings

    $ATXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astria Stockholders Vote to Approve Acquisition by BioCryst

    Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger"). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. About Astria Therapeutics Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinica

    1/21/26 4:00:00 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    -- BioCryst's Acquisition of Astria Expected to Close in the First Quarter of 2026 -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial -- -- Final Phase 1b/2 ALPHA-STAR Results in 29 HAE Patients Reinforces Navenibart's Robust HAE Attack Prevention and Favorable Safety Profile -- -- STAR-0310, an OX40 Antagonist, Demonstrated a Best-In-Class Profile with Initial Phase 1a Data Presented at the European Academy of Dermatology and Venereology Congress -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing l

    11/12/25 8:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

    -- Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy, Favorable Safety, and Potential for Infrequent Dosing -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the AL

    11/6/25 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.

    SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    2/9/26 5:03:25 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Astria Therapeutics Inc.

    15-12G - Astria Therapeutics, Inc. (0001454789) (Filer)

    2/2/26 4:05:16 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.

    SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    1/28/26 8:38:48 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $29,999,522 worth of shares (2,481,350 units at $12.09) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    2/5/24 5:02:33 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $4,588,000 worth of shares (740,000 units at $6.20) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    12/22/23 2:51:57 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perceptive Advisors Llc bought $6,999,997 worth of shares (1,074,608 units at $6.51) (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    10/18/23 4:11:36 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Astria Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Astria Therapeutics from Overweight to Neutral

    11/12/25 12:18:19 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Astria Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously

    9/17/25 11:36:24 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

    4/29/25 8:10:45 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Violin Jonathan returned 263,321 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    1/23/26 4:37:09 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Morabito Christopher

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    1/23/26 4:35:24 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Milne Jill C. returned 4,377 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    1/23/26 4:33:25 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:46:12 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:45:56 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Astria Therapeutics Inc.

    SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 4:41:28 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Financials

    Live finance-specific insights

    View All

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that the companies have entered into a definitive agreement under which BioC

    10/14/25 7:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

    -- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological

    3/25/24 7:30:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    Leadership Updates

    Live Leadership Updates

    View All

    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

    4/9/24 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care